A novel scoring system for selecting the target patients of COVID-19 convalescent plasma therapy: A hypothesis

Bansal, Nalini; Raturi, Manish; Bansal, Yashik; Singh, Pushpendra

doi:10.1016/j.tracli.2021.06.004

Cited by 5 publications

(1 citation statement)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… In patients with COVID-19, CP treatment is secure and might be helpful. Naveen Bansal et al 138 An innovative system of grading to identify which COVID-19 CPT individuals need to receive special attention: a conclusion from a hypothesis Based on this grading methodology, 2 groups of patients are created. Group at low risk (LRG; score <5) Group at high risk (HRG; score ≥5) Score 0–4: No intervention (Basic standard care and hospital management) Score of ≥5: Early CP therapy, preferably before 72 hours To destroy the SARS-CoV-2 virus and prevent the CS from emerging, HRG should begin CP therapy within 72 hours following a definitive diagnosis of COVID-19.…”

Section: Introductionmentioning

confidence: 99%

Effectiveness of COVID-19 Convalescent Plasma (CCP) During the Pandemic Era: A Literature Review

Kandula¹,

Tuji²,

Gudeta³

et al. 2023

JBM

View full text Add to dashboard Cite

Worldwide pandemic with coronavirus disease-2019 (COVID-19) was caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). As November 2, 2022, World Health Organization (WHO) received 628,035,553 reported incidents on COVID-19, with 6,572,800 mortalities and, with a total 12,850,970,971 vaccine doses have been delivered as of October 31, 2022. The infection can cause mild or self-limiting symptoms of pulmonary and severe infections or death may be caused by SARS-CoV-2 infection. Simultaneously, antivirals, corticosteroids, immunological treatments, antibiotics, and anticoagulants have been proposed as potential medicines to cure COVID-19 affected patients. Among these initial treatments, COVID-19 convalescent plasma (CCP), which was retrieved from COVID-19 recovered patients to be used as passive immune therapy, in which antibodies from cured patients were given to infected patients to prevent illness. Such treatment has yielded the best results in earlier with preventative or early stages of illness. Convalescent plasma (CP) is the first treatment available when infectious disease initially appears, although few randomized controlled trials (RCTs) were conducted to evaluate its effectiveness. The historical record suggests with potential benefit for other respiratory infections, as coronaviruses like Severe Acute Respiratory Syndrome-CoV-I (SARS-CoV-I) and Middle Eastern Respiratory Syndrome (MERS), though the analysis of such research is constrained by some non-randomized experiments (NREs). Rigorous studies on CP are made more demanding by the following with the immediacy of the epidemics, CP use may restrict the ability to utilize it for clinical testing, non-homogenous nature of product, highly decentralized manufacturing process; constraints with capacity to measure biologic function, ultimate availability of substitute therapies, as antivirals, purified immune globulins, or monoclonal antibodies. Though, it is still not clear how effectively CCP works among hospitalized COVID-19 patients. The current review tries to focus on its efficiency and usage in clinical scenarios and identifying existing benefits of implementation during pandemic or how it may assist with future pandemic preventions.

show abstract